These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36632223)

  • 1. Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m
    Zhao Y; Wen S; Li H; Pan CW; Wei Y; Huang T; Li Z; Yang Y; Fan S; Zhang Y
    Theranostics; 2023; 13(2):596-610. PubMed ID: 36632223
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional roles of antisense enhancer RNA for promoting prostate cancer progression.
    Pan CW; Wen S; Chen L; Wei Y; Niu Y; Zhao Y
    Theranostics; 2021; 11(4):1780-1794. PubMed ID: 33408781
    [No Abstract]   [Full Text] [Related]  

  • 3. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine.
    Wen S; Wei Y; Zen C; Xiong W; Niu Y; Zhao Y
    Mol Cancer; 2020 Dec; 19(1):171. PubMed ID: 33308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
    Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
    Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
    Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
    Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
    Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
    Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
    Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
    J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.
    Bachmann SB; Frommel SC; Camicia R; Winkler HC; Santoro R; Hassa PO
    Mol Cancer; 2014 May; 13():125. PubMed ID: 24886089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
    Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
    Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.
    Josson S; Matsuoka Y; Gururajan M; Nomura T; Huang WC; Yang X; Lin JT; Bridgman R; Chu CY; Johnstone PA; Zayzafoon M; Hu P; Zhau H; Berel D; Rogatko A; Chung LW
    PLoS One; 2013; 8(7):e68366. PubMed ID: 23874600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of CXCR4-small interfering RNA retrovirus vector driven by human prostate-specific antigen promoter and its biological effects on prostate cancer in vitro and in vivo.
    Du YF; Shi Y; Xing YF; Zeng FQ
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1255-64. PubMed ID: 18431597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma.
    Li HB; Huang G; Tu J; Lv DM; Jin QL; Chen JK; Zou YT; Lee DF; Shen JN; Xie XB
    EBioMedicine; 2022 Aug; 82():104142. PubMed ID: 35810559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.